Effectiveness of Drip Infusion of Lascufloxacin, a Novel Fluoroquinolone Antibiotic, for Patients with Pneumonia Including Chronic Lung Disease Exacerbations and Lung Abscesses
Daishi Shimada,Masafumi Seki
DOI: https://doi.org/10.2147/idr.s453634
2024-03-09
Infection and Drug Resistance
Abstract:Daishi Shimada, 1 Masafumi Seki 1, 2 1 Division of Infectious Diseases, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Japan; 2 Division of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka City, Japan Correspondence: Masafumi Seki, Division of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Yamane 1397-1, Hidaka City, Saitama, 350-1298, Japan, Tel +81-42-984-4392, Fax +81-42-984-0280, Email Background: Lascufloxacin (LSFX), a novel fluoroquinolone antibacterial agent, has recently been used as a drip infusion for treating pneumonia, apparently with good effectiveness against various bacteria, including anaerobes, and good intrapulmonary penetration. Methods: The clinical effectiveness of LSFX was retrospectively investigated for the 55 patients admitted to our hospital with pneumonia, including chronic lung disease exacerbations and lung abscesses, from May 2021 to July 2023. Results: The median age of the 55 patients was 76.1 (34.1– 93.1) years, 45 (81.8%) were male, and 48 (87.5%) patients had underlying disease. Community-acquired pneumonia was seen in 47 (85.5%) patients, including 9 (16.4%) with lung abscess, and the other 8 (14.5%) had nursing and healthcare-associated pneumonia/hospital-acquired pneumonia. Moderate pneumonia was present in 33 (61.8%) of 55 patients, and LSFX was used as a second-line treatment for 28 (50.9%) patients in whom first-line antibiotics were ineffective. The median duration of intravenous LSFX administration was 9 (2.0– 49) days. Streptococcus pneumoniae and methicillin-susceptible Staphylococcus aureus were isolated from 3 (7.1%) and 2 (4.8%) patients, respectively. Of the 55 patients, 45 (81.5%) improved clinically with intravenous LSFX administration; 20 (95.2%) of 21 community-acquired pneumonia cases, including 9 (100.0%) of 9 bacterial pneumonia cases, were improved by LSFX as first-line treatment, and 8 (88.9%) of 9 lung abscess patients also showed clinical improvement with LSFX as a second-line treatment. There were no severe adverse effects in any of the 55 patients. Conclusion: Based on these data, intravenous administration of LSFX seems effective for bacterial pneumonia, including chronic lung disease exacerbations and lung abscesses, and it appears to have broad antimicrobial activity and good tissue penetration into the lung. Keywords: aspiration pneumonia, empyema, fluoroquinolone, lascufloxacin, lung abscess Pneumonia, especially aspiration pneumonia, is a significant issue in a high-age society, including Japan, because pneumonia is associated with higher morbidity and mortality in elderly patients than in younger patients. 1,2 The clinical importance of pneumonia in elderly persons relates to age-dependent and pathological changes in the immune system, as well as lung functions. In fact, pneumonia is a major infection that has been in the top three to five of the leading death causes in Japan, and aspiration pneumonia is known to be one of the important types of nursing- and healthcare-associated pneumonia (NHCAP). 3,4 Aspiration pneumonia could be a life-threatening condition in elderly persons, such as those with severe hemoptysis, and mortality rates might be as high as 15–20%. 1,4 The initial step in the pathogenesis of these diseases is usually aspiration of infectious material from the oropharynx or stomach. Therefore, a mixed spectrum, including anaerobic, microaerobic, and aerobic microorganisms makes up the expected microbiological flora, 1,4 and penicillin G had been the first choice antibiotic for a long time, until it was outperformed by ampicillin/sulbactam (ABPC/SBT) or clindamycin. 5 Furthermore, third- and fourth-generation cephalosporins, piperacillin, and fluoroquinolones (FQs) have recently been recommended. 6,7 In addition, as a complication of aspiration pneumonia, lung abscesses are indolent at onset, and they complicate acute mono- or poly-microbial infections with pyogenic bacteria, including Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus , and anaerobic bacteria. 4,6,8 Lung abscesses can also result from secondary infection of pre-existing lung cavities, bronchial obstruction, septic embolization, or direct extension from local infections such as empyema. Inflamed tissue usually surrounds the pus-filled cavity in lung abscesses and shows the typical round-shape formation on chest X-ray photographs and computed tomography (CT). 6,9 Therefore, lung abscesses are difficult to treat by common antibiotics, such as cephalosporins and penicillins, -Abstract Truncated-
pharmacology & pharmacy,infectious diseases